4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers

Renal Cell ◽

Phase 2 ◽

Circulating Biomarkers ◽

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2016.12.023 ◽

2017 ◽

Vol 35 (3) ◽

pp. 117-118 ◽

Cited By ~ 2

Author(s):

Raman Jay ◽

RR McKay ◽

L Werner ◽

MB Atkins ◽

EM Van Allen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Poor Risk ◽

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

BMC Cancer ◽

10.1186/s12885-018-4091-5 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Lin Yang ◽

Anna Alyasova ◽

Dingwei Ye ◽

Antonia Ridolfi ◽

Luca Dezzani ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30196-6 ◽

2016 ◽

Vol 17 (9) ◽

pp. 1317-1324 ◽

Cited By ~ 93

Author(s):

Brian I Rini ◽

Tanya B Dorff ◽

Paul Elson ◽

Cristina Suarez Rodriguez ◽

Dale Shepard ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Active Surveillance ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Prospective Phase

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70464-9 ◽

2013 ◽

Vol 14 (12) ◽

pp. 1233-1242 ◽

Cited By ~ 157

Author(s):

Brian I Rini ◽

Bohuslav Melichar ◽

Takeshi Ueda ◽

Viktor Grünwald ◽

Mayer N Fishman ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Dose Titration ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.8167 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 8167-8167 ◽

Cited By ~ 2

Author(s):

J. Beaumont ◽

D. Cella ◽

J. Li ◽

R. Motzer ◽

B. Rini ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Patient Reported Outcomes ◽

Phase 2 ◽

Phase 2 Trial ◽

Patient Reported

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

Cancer ◽

10.1002/cncr.29503 ◽

2015 ◽

Vol 121 (19) ◽

pp. 3435-3443 ◽

Cited By ~ 43

Author(s):

M. Dror Michaelson ◽

Rana R. McKay ◽

Lillian Werner ◽

Michael B. Atkins ◽

Eliezer M. Van Allen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Poor Risk ◽

TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of Oncology ◽

10.1093/annonc/mdw373.78 ◽

2016 ◽

Vol 27 ◽

pp. vi295

Author(s):

T. Choueiri ◽

N. Agarwal ◽

T. Ho ◽

S.K. Pal ◽

B. Seon ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

239O RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis

Annals of Oncology ◽

10.1093/annonc/mdv524.04 ◽

2015 ◽

Vol 26 ◽

pp. ix71

Author(s):

L. Yang ◽

A. Alyasova ◽

D. Ye ◽

A. Karpenko ◽

H. Li ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase

P0201 Circulating biomarkers and outcomes in a phase 2 trial of first-line everolimus alternating with sunitinib for advanced renal cell carcinoma (ANZUP 0901—the EVERSUN Trial)

European Journal of Cancer ◽

10.1016/j.ejca.2014.03.245 ◽

2014 ◽

Vol 50 ◽

pp. e65

Author(s):

S. Yip ◽

N. Pavlakis ◽

R. Harvie ◽

A. Martin ◽

A. Hudson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Phase 2 ◽

Circulating Biomarkers ◽

First Line ◽

2634 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis

European Journal of Cancer ◽

10.1016/s0959-8049(16)31451-4 ◽

2015 ◽

Vol 51 ◽

pp. S524

Author(s):

L. Yang ◽

A. Alyasova ◽

D. Ye ◽

A. Karpenko ◽

H. Li ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase